Sobi Appoints Guido Oelkers as New President and CEO
Previously he worked as CEO at BSN Medical GmbH. He has extensive experience from pharmaceutical and health care companies including a role as President and CEO of Gambro, Invida and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group and Aventis (formerly Hoechst), where he began his career. Guido Oelkers was also a member of the Board of Directors for Meda. Guido Oelkers holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London. He complemented his postgraduate studies in Economics at London School of Economics and Political Science.
Sobi Chairman,Håkan Björklund said that they are delighted to announce Guido’s appointment. He has created substantial shareholder value in his various positions. Guido is a results-driven strategist and an entrepreneur at heart who has demonstrated impressive resourcefulness and creativity in his previous roles. Guido is the right person to further develop Sobi’s strategy as a pioneering biotechnology company, expanding upon the journey for our successful global brands, and realise the remarkable potential in their haemophilia franchise. The Board would also like to thank Geoffrey McDonough for his significant contribution and the remarkable value he has created during his term as CEO at Sobi.